2015 Chinese Hepatitis B Guidelines: Treatment endpoints for chronic hepatitis B: 1. Desirable endpoints: HBeAg-positive versus HBeAg-negative patients who obtain durable HBsAg disappearance with or without HBsAg serologic conversion after drug discontinuation. 2. Satisfactory endpoints: HBeAg-positive patients with sustained virological response and ALT normalization with HBeAg serological conversion after drug discontinuation; HBeAg-negative patients with sustained virological response and ALT normalization after drug discontinuation. 3.Essential endpoints: long-term maintenance of virological response (undetectable HBV DNA) during antiviral therapy if sustained response after drug discontinuation cannot be obtained. 4. Efficacy data: (1) Long-acting interferon: HBeAg-positive chronic hepatitis B patients treated for 48 weeks, with a HBeAg serological conversion rate of 32%-36% and HBsAg conversion rate of 2.3%-3% at 24 weeks of discontinuation follow-up. HBeAg-negative chronic hepatitis B patients The rate of HBsAg disappearance was 3% at 48 weeks of treatment and increased to 8.7% at 3 years of discontinuation follow-up and 12% at 5 years of discontinuation. (2) ETV long-term treatment follow-up study shows that HBeAg-positive chronic hepatitis B patients treated for 5 years, HBV DNA conversion rate up to 94%, ALT normalization rate of 80% (3) Tibivudine, if HBV DNA 300 copies/mL at 24 weeks of treatment, treatment to 1 year, 2 years have better efficacy and lower incidence of drug resistance (4) Tenofovir disoproxil fumarate (4) Tenofovir disoproxil fumarate: In HBeAg-positive chronic hepatitis B patients, the rate of HBV DNA conversion at 48 weeks of treatment was 76%, the rate of HBeAg serological conversion was 21%, and the rate of ALT normalization was 68%. In HBeAg-negative chronic hepatitis B patients, the HBV DNA conversion rate was 93% and the ALT normalization rate was 76% at 48 weeks of treatment. Dr. Ma’s interpretation: 1. The ideal endpoint, which is marked by the appearance of HBsAg conversion to negative and in some cases HBsAb positivity. This means that hepatitis B is clinically cured and the likelihood of lifelong stability of hepatitis B after drug discontinuation is greatest. It is relatively rare, but has been seen in the clinic, especially in patients using long-acting interferon. 2, satisfactory endpoint: for HBeAg positive hepatitis B, the sign is the emergence of HBeAg turn negative, the emergence of HBeAb positive, which is usually referred to as the major triplet to minor triplet. This means that the hepatitis B disease is stable and the chances of relapse are much smaller than for patients with major triplets. For HBeAg-negative hepatitis B, the sign is the appearance of long-term appearance of HBVDNA can not be measured, liver function is normal. It is currently more common clinically, mostly in patients who use interferon or nucleoside analogs for long-term antiviral treatment. 3. The basic endpoint, after the current use of antiviral therapy, is the basic goal. If HBVDNA is still repeatedly positive, suggesting poor treatment effect or treatment failure, timely consultation is needed to change the treatment plan. 4, therefore, chronic hepatitis B patients, through reasonable and appropriate antiviral treatment, most of them can obtain the above treatment endpoints, which can achieve control of disease progression and effectively delay the risk of cirrhosis, liver cancer. However, the condition is that the antiviral needs to be long enough. Are you able to do so? If so, congratulations, hepatitis B will not pose a threat to your health!